Cannara Biotech (LOVE.V) Stock Price

Cannara Biotech Price

TSX·CLOSED
2.12
​
Market closed

Over the last 6 years Cannara Biotech grew revenue by 92.7% annually, reaching 107.32 M CAD. Earnings per share have grown at 75.4% per year over the last 3 years. For Cannara Biotech, the net margin of 12.2% is up versus -8.8% a few years ago. The consensus 12-month price target for Cannara Biotech is 3.57 CAD, about 68.4% above where the stock trades today. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus.

Cannara Biotech stock price

Access this data via the Eulerpool API

Cannara Biotech business model & stock analysis

Cannara Biotech, Inc. engages in the production of premium-grade cannabis and cannabis-derivative products. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2019-01-14. The company operates through its wholly owned subsidiaries, Cannara Biotech (Quebec) Inc. and Cannara Biotech (Valleyfield) Inc. The firm owns two mega facilities based in Quebec spanning over 1,650,000 square feet, providing the Company with 100,000 kilograms of annualized cultivation output. The company operates in two segments: Cannabis operations and Real estate operations. The Cannabis operations, which encompasses the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and other cannabis services (Cannabis operations). The Real estate operations, related to the Farnham and Valleyfield building (Real estate operations). The Company’s brand portfolio includes Tribal, Nugz, and Orchid CBD. Orchid CBD is a wellness brand that provides premium CBD-dominant cannabis.

Frequently asked questions about Cannara Biotech

Analysts currently set an average price target of 3.57 CAD for the Cannara Biotech stock (median: 3.57 CAD), implying +68.4 % versus the latest price. The consensus is based on 5 analyst ratings.

5 analysts currently rate the Cannara Biotech stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Cannara Biotech to generate revenue of 129.12 M CAD and earnings per share of 0.17 CAD.

Converted at the current exchange rate, the Cannara Biotech share trades at 1.33 EUR (2.12 CAD).

The Cannara Biotech share (LOVE.V) is listed on 3 stock exchanges, including: Toronto (LOVE.V), Frankfurt (8CB0.F).

The expected revenue of Cannara Biotech is 129.12 M CAD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Cannara Biotech is 15.32 M CAD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Cannara Biotech is currently 12.78. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Cannara Biotech stock.

The price-to-sales ratio (P/S) of Cannara Biotech is currently 1.52. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Cannara Biotech stock.

The Eulerpool Quality Score for Cannara Biotech is 4/10.

The ISIN of Cannara Biotech is CA13765U2002. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Cannara Biotech is A3D495. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Cannara Biotech is LOVE.V. The ticker symbol is used to trade Cannara Biotech shares on the stock exchange.

Fair ValueTerminal
1.89 CAD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website cannara.ca
Country
Currency
CAD
Initial public offering
Jan 14, 2019
ISIN
CA13765U2002
Cusip
13765U200
Market capitalization
203.05 M CADMicro Cap
52-Week Range
PEG
0.79
P/E ratio
P/Ee 2026
13.25
P/Ee 2027
10.60
P/Ee 2028
7.85
P/S
P/Se
1.52
EV/EBIT
—
P/B Ratio
1.99
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
9.09 %
Last updated Oct 9, 2026, 7:54 AM

Cannara Biotech Peer Group

Cannara Biotech Ticker

FRANKFURT · 8CB0.FOTC · LOVFFTSX · LOVE.V

Cannara Biotech FIGI

LOVE:CN · BBG00LGMXNR1LOVE:CV · BBG00N26S9Z5LOVE:CJ · BBG00N26SB35LOVE:TV · BBG00N26SB62LOVE:TN · BBG00N26SB99LOVE:TG · BBG00N26SBB6LOVE:TK · BBG00N26SBC5LOVE:TW · BBG00N26SBD4LOVE:DV · BBG00N26SBH0LOVE:DS · BBG00N26SBJ8LOVE:DG · BBG00N26SBL5LOVE:QF · BBG00N26SBM4